GILDGilead Issues $3B Senior Notes maturing 2028–2034
Gilead raises $3B through senior notes maturing 2028–2034 with coupons 4.25%–4.9%. Investor context on revenue mix, pipeline assets, and material risks.
GILEAD SCIENCES, INC.
GILDGILD: Board Restructuring Linked to Merger
Arcellx directors and officers resign; Gilead executives to assume roles. Strategic tie to Gilead's CAR‑T oncology push and existing pipeline.
GILEAD SCIENCES, INC.
GILDGILD: FDA Accepts Arcellx Anito-cel BLA
Feb 23, 2026 — FDA accepts Arcellx's BLA for anito-cel, advancing Gilead's CAR-T exposure; investors should monitor regulatory milestones and program risks.
GILEAD SCIENCES, INC.
GILDGilead to Acquire Arcellx at $115 + CVRs
Feb 23, 2026 — Gilead (GILD) agrees to acquire Arcellx for $115/share plus CVRs, adding a BLA‑filed CAR‑T program to its oncology pipeline.
GILEAD SCIENCES, INC.
GILDGILD: Gilead Acquires Interius BioTherapeutics
Gilead (GILD) acquires Interius BioTherapeutics to expand its cell therapy and CAR-T portfolio — implications for oncology pipeline, revenues, and investor risk.
GILEAD SCIENCES, INC.
GILDGILD Dividend Raised to $0.79 — Q4 2025
Gilead (GILD) board declares Q4 2025 quarterly dividend of $0.79/share, up from $0.77. Read analyst-focused context on cash drivers, pipeline and risks.
GILEAD SCIENCES, INC.
GILDGilead Advances HIV, Cell Therapy; Acquires Interius
Gilead (GILD) secures regulatory approvals and acquires Interius BioTherapeutics to bolster HIV and cell therapy pipelines; investor implications analyzed.
GILEAD SCIENCES, INC.
GILDGilead Advances HIV Prevention Portfolio
Gilead (GILD) strengthens HIV prevention with lenacapavir NDA, strategic partnerships and Biktarvy patent extension, reinforcing its PrEP and HIV franchise.
GILEAD SCIENCES, INC.
GILDGilead (GILD) Partners to Expand HIV PrEP
Gilead teams with the U.S. government and PEPFAR to expand global HIV PrEP delivery. Investor note: implications for the HIV franchise, lenacapavir NDA and revenue exposure.
GILEAD SCIENCES, INC.
GILDGilead Raises 2025 EPS & Sales Guidance
Gilead (GILD) raised its 2025 EPS and product sales guidance on Oct 30, 2025, supported by HIV product strength and U.S. sales concentration.
GILEAD SCIENCES, INC.
GILDMoody’s Upgrades Gilead Outlook; A3 Affirmed
Moody’s affirms Gilead (GILD) A3 rating and upgrades outlook to positive on 2025-10-30. Key implications for credit profile, revenue drivers and investor risks.
GILEAD SCIENCES, INC.
GILDGILD Q3 2025: Revenue Up, EPS $2.43
Gilead (GILD) Q3 2025 results: revenue +3% y/y, EPS $2.43. Key drivers, Biktarvy patent update, pipeline and risks for investors.
GILEAD SCIENCES, INC.
GILDGILD Q3 2025: Revenue +3%, Patent Extension
Gilead (GILD) Q3 2025: revenues +3% YoY, Biktarvy patent extended to 2036, Moody's upgrades credit outlook, and board raises dividend.
GILEAD SCIENCES, INC.
GILDGilead Q3 2025: Revenue Up 3%, EPS $2.43
Gilead (GILD) Q3 2025 revenue rose 3% and EPS more than doubled to $2.43. Key drivers, product mix, patent context and investor risks explained.
GILEAD SCIENCES, INC.
GILDGILD Q3: Revenue +3% & Dividend Hike
Gilead (GILD) Q3 revenue rose 3%; quarterly dividend increased and Biktarvy patent settlement extends exclusivity to 2036. What investors should know.
GILEAD SCIENCES, INC.
GILDGilead Q3 Updates: Patent Deal, Dividend & Outlook
Gilead (GILD) Q3 update: company reports results, patent settlement extending Biktarvy to 2036, dividend actions and management outlook for investors.
GILEAD SCIENCES, INC.
GILDGilead Raises 2025 EPS & Sales Guidance (GILD)
Gilead (GILD) raised full-year 2025 EPS and sales guidance, citing stronger HIV franchise and U.S. product sales. Outlook, risks, and pipeline context for investors.
GILEAD SCIENCES, INC.
GILDGilead Advances HIV and Oncology Portfolio
Gilead (GILD) secures approval for lenacapavir and acquires Interius BioTherapeutics, bolstering HIV and oncology pipelines; analysis of revenue, risks, and investor implications.
GILEAD SCIENCES, INC.
GILDGilead Expands HIV Prevention Efforts
Gilead (GILD) partners with U.S. agencies and acquires Interius BioTherapeutics to bolster HIV prevention and PrEP programs, complementing its lenacapavir work.
GILEAD SCIENCES, INC.
GILDGILD: 2025 EPS Guidance Raised
Gilead raises 2025 EPS and product-sales guidance. Investors watch HIV franchise (Biktarvy), U.S. revenue concentration and pipeline catalysts.
GILEAD SCIENCES, INC.
GILDGilead Advances HIV PrEP Partnerships — GILD
Gilead (GILD) advances HIV prevention with lenacapavir NDA for once-yearly PrEP, strategic collaborations including Merck, and a HIV franchise led by Biktarvy.
GILEAD SCIENCES, INC.
GILDGilead Raises Q4 2025 Dividend to $0.79
Gilead Sciences (GILD) raises Q4 2025 dividend to $0.79 from $0.77. Investor-focused analysis, company context, and key risks.
GILEAD SCIENCES, INC.
GILDGilead Q3 2025: Revenue +3%, EPS $2.43
Gilead (GILD) Q3 2025 results: revenue up 3%, EPS rises to $2.43. Analysis of drivers, HIV franchise strength, pipeline and investor risks.
GILEAD SCIENCES, INC.
GILDGilead Raises 2025 EPS Guidance
Gilead (GILD) raises full-year 2025 EPS and product sales outlook. Investors should watch HIV franchise performance, product sales mix and regulatory risks.
GILEAD SCIENCES, INC.
GILDGILD: Biktarvy Patent Exclusivity Extended to 2036
Gilead settles patent disputes, securing Biktarvy exclusivity through 2036 and blocking generics. Q1 2025 Biktarvy sales: $3.15B; HIV products core revenue.
GILEAD SCIENCES, INC.